Kidney More ¢ò Particle Treatment Of Chronic Nephritis Clinical Research

OBJECTIVEThe goal of this clinical experiment is to probe the mechanism and therapeutic effect of Shenyu II infusing Prescription(SYP) on treating Chronic Glomerulonephritis (CGN), and search an effectual method of TCM in treating CGN.METHODS60 patients with CGN were divided into 2 groups at random: SYP therapeutic group(Group A, n=30). Four Tastestablet for Nephritis control group (Group B, n=30). According to the requirement of disease both groups were treated with controlling blood pressure and diuresis. Group A took SYP two times daily, lOg each time. Group B took Four Tastestablet for Nephritis three times daily,8 tablets each time.The therapeutic period was two months. Before and after experiment, we assayed the patient's Haemoglobin, 24hupq, ALB, ALT, BUN, Scr, blood soluble interleukin-2 receptor (sIL-2R), blood thromboxane B2(TXB2)and 6-keto-prostaglandin F1a (6-k-PGF1a). Recorded the change of patients' clinical symptoms. at last, observed the difference of therapeutic effect between group A and group B.RESULTResult of the study could be summarized as:1 The total effective rate of group A was 86. 67%,while group B was 66. 67%, the total therapeutic effect of group A was better than that of group B (p<0. 01).2 SYP could improve the patients'clinical symptoms, the effects was better than group B (p<0. 01) .3 SYP could decrease urinary protein, BUN, Scr. increase ALB and Hb signif icantly( p<0. 01). The effects of decrease urinary protein, Bun, Scr and increase ALB,Hb was better than group B (p<0. 01 or p<0. 05) .4 All patients' blood sIL-2R, TXBa were higher and 6-keto-PGF1a, was lower than that of general persons. SYP could decrease blood sIL-2R, TXB2 and increase blood 6-keto-PGF1a significantly (p<0. 01 or p<0. 05) . It is effects was better than group B (p<0. 05) .5 SYP could decrease the patients' BUN, Scr, sIL-2R of two symptom-complexs (Qi-def iciency of both spleen and kidney coexisting blood statis and coexisting water) significantly (p<0. 01 or p<0. 05 ) . To the symptom-complexs (Qi-def iciency of both spleen and kidney coexisting blood statis. The SYP's effective of decrease BUN, Scr, sIL-2R was better than group B (p<0. 05) .but that is not to the symptom-complexs of Qi-def iciency of both spleen and kidney coexisting water (p>0. 05).6 The result of experiment indicated: there were significantly interrelation between blood sIL-2R and BUN, between sIL-2R and Scr (r=0. 58, r=0.55; P< 0. 01) .CONCLUSIONThe alteration of sIL-2R and TXA2-PGI2 could play a important role in CGN. SYP could improve renal function and clinical symptoms, decrease proteinuria and sIL-2R, adjust the balance of TXA2-PGI2. SYP therapy could markedly retard the rate of progression of CGN. The mechanism may be concerned with it is regulating immunity and improving renal dynamics of blood flow.